Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil immunotherapy in ovarian cancer
NCT02346747Phase 2Active, not recruiting
- Sponsor
- Gradalis, Inc.
- Start
- Feb 2015
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Group A: Vigil with Group B: Placebo (2 arms). Primary endpoint: Recurrence Free Survival up to 10 years. Started Feb 2015; status: active, not recruiting.
02
Drugs
gemogenovatucel-T
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02346747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346747.